AKT1 and neoplasm: Over expression of DCBLD223 may act as an oncogene interacting with the EGFR and PI3K/Akt signaling pathways; gain of function of DCBLD2 mutation (Indel) could participate with cellular proliferative pathways to promote tumor progression.